| scholarly article | Q13442814 |
| P50 | author | Pete Clifton | Q64026184 |
| P2093 | author name string | Nicholas A Moore | |
| Abegale W Hartfield | |||
| P2860 | cites work | Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors | Q28119146 |
| Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding | Q28297725 | ||
| Bodyweight gain with atypical antipsychotics. A comparative review | Q32060406 | ||
| Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group | Q33178075 | ||
| Atypical antipsychotics and weight gain--a systematic review | Q33951215 | ||
| H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. | Q33964839 | ||
| Norepinephrine and the control of food intake | Q34071828 | ||
| Brain histamine and feeding behavior | Q34407487 | ||
| SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist | Q34432766 | ||
| Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group | Q34719739 | ||
| Mechanism of the body weight increase induced by systemic sulpiride | Q41324029 | ||
| Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain | Q42242452 | ||
| Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine | Q42274823 | ||
| Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial | Q42550364 | ||
| Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats. | Q42690622 | ||
| Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone | Q43622360 | ||
| Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients | Q43638445 | ||
| Elevation of prolactin levels by atypical antipsychotics | Q43843058 | ||
| Studies on modulation of feeding behavior by atypical antipsychotics in female mice | Q43870639 | ||
| Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. | Q43913101 | ||
| Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia | Q43922937 | ||
| The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study | Q43956675 | ||
| Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine | Q44013107 | ||
| Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance | Q44223742 | ||
| Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. | Q44377337 | ||
| Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake | Q44520669 | ||
| Serotonergic and histaminergic mechanisms involved in intralipid drinking? | Q44638855 | ||
| Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group | Q46228316 | ||
| Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? | Q47194368 | ||
| Diurnal changes in paraventricular hypothalamic alpha1 and alpha2-adrenoceptors and food intake in rats | Q48203133 | ||
| Behavioral mechanisms for the anorectic action of the serotonin (5-HT) uptake inhibitor sertraline in rats: comparison with directly acting 5-HT agonists | Q48848141 | ||
| Radioreceptor binding profile of the atypical antipsychotic olanzapine | Q49130929 | ||
| Serum leptin levels increase rapidly after initiation of clozapine therapy | Q57338243 | ||
| Switch from neuroleptics to clozapine does not influence pituitary–gonadal axis hormone levels in male schizophrenic patients | Q60619405 | ||
| Free-feeding and free-drinking patterns of male rats following treatment with opiate kappa agonists | Q67509259 | ||
| Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study | Q67536643 | ||
| ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group | Q71216981 | ||
| Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial | Q71816819 | ||
| Repeated 2-deoxy-D-glucose-induced glucoprivation attenuates Fos expression and glucoregulatory responses during subsequent glucoprivation | Q73190279 | ||
| Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group | Q73437452 | ||
| Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group | Q73625752 | ||
| Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial | Q77708314 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1938-1945 | |
| P577 | publication date | 2005-11-02 | |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats | |
| P478 | volume | 31 |
| Q46070377 | Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats |
| Q38850666 | Atypical antipsychotics and effects on feeding: from mice to men. |
| Q51185707 | Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. |
| Q46217077 | Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. |
| Q28478539 | Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation |
Search more.